HomeCompareSMPEF vs ABBV

SMPEF vs ABBV: Dividend Comparison 2026

SMPEF yields 2844.95% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMPEF wins by $274339726778.81M in total portfolio value
10 years
SMPEF
SMPEF
● Live price
2844.95%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$274339726778.92M
Annual income
$256,597,217,201,022,270.00
Full SMPEF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SMPEF vs ABBV

📍 SMPEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMPEFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMPEF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMPEF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMPEF
Annual income on $10K today (after 15% tax)
$241,820.77/yr
After 10yr DRIP, annual income (after tax)
$218,107,634,620,868,930.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SMPEF beats the other by $218,107,634,620,847,870.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMPEF + ABBV for your $10,000?

SMPEF: 50%ABBV: 50%
100% ABBV50/50100% SMPEF
Portfolio after 10yr
$137169863389.51M
Annual income
$128,298,608,600,523,520.00/yr
Blended yield
93.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SMPEF
No analyst data
Altman Z
-21.1
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMPEF buys
0
ABBV buys
0
No recent congressional trades found for SMPEF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMPEFABBV
Forward yield2844.95%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$274339726778.92M$102.3K
Annual income after 10y$256,597,217,201,022,270.00$24,771.77
Total dividends collected$273109467375.37M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMPEF vs ABBV ($10,000, DRIP)

YearSMPEF PortfolioSMPEF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$295,195$284,495.02$11,550$430.00+$283.6KSMPEF
2$8,164,598$7,848,739.62$13,472$627.96+$8.15MSMPEF
3$211,617,382$202,881,261.64$15,906$926.08+$211.60MSMPEF
4$5,140,877,810$4,914,447,211.39$19,071$1,382.55+$5140.86MSMPEF
5$117,078,294,503$111,577,555,246.33$23,302$2,095.81+$117078.27MSMPEF
6$2,500,101,823,429$2,374,828,048,310.65$29,150$3,237.93+$2500101.79MSMPEF
7$50,069,800,524,078$47,394,691,573,009.04$37,536$5,121.41+$50069800.49MSMPEF
8$940,657,342,395,257$887,082,655,834,493.20$50,079$8,338.38+$940657342.35MSMPEF
9$16,581,784,652,237,514$15,575,281,295,874,588.00$69,753$14,065.80+$16581784652.17MSMPEF
10$274,339,726,778,916,400$256,597,217,201,022,270.00$102,337$24,771.77+$274339726778.81MSMPEF

SMPEF vs ABBV: Complete Analysis 2026

SMPEFStock

Southern Empire Resources Corp. engages in the acquisition, exploration, and development of metal and mineral resources in North America. The company has an option to acquire 100% interest in the Oro Cruz Property covering an area of 2,160 hectares located in the Cargo Muchacho mountains of Imperial County, southeast California; and option to acquire 100% interest in Pedro Gold Project covering an area of 1,750 hectares located in Durango State, Mexico. It also owns an 85% interest in the Eastgate Gold project comprising 101 unpatented lode mining claims covering an area of 817 hectares located in Churchill County, Nevada. The company was formerly known as Owl Capital Corp. and changed its name to Southern Empire Resources Corp. in March 2018. Southern Empire Resources Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full SMPEF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SMPEF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMPEF vs SCHDSMPEF vs JEPISMPEF vs OSMPEF vs KOSMPEF vs MAINSMPEF vs JNJSMPEF vs MRKSMPEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.